On 21 October 2022, the Spanish National Markets and Competition Commission (CNMC) imposed a €38.9 million fine on pharmaceutical company Merck Sharp and Dohme (MSD) for abusing its dominant position in the Spanish market for contraceptive vaginal rings. In particular, the CNMC concluded that MSD conducted a litigation strategy against Insud Pharma, a competing company, which delayed the entry of competing product “Ornibel” into the Spanish market. The CNMC’s decision shows competition authorities’ increasing interest in the pharmaceutical sector and, specifically, in the misuse of litigation strategies by pharma companies with the aim of delaying the entry of generics into the market. The infringing conduct: unjustified legal actions MSD is a pharmaceutical company that held the patent
Share on
|
|
The Spanish Competition Authority imposes sanctions on a pharmaceutical company for misusing litigation strategies regarding patents (Merck Sharp & Dohme)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.
